- Expertise:
-
Lung Cancer
Esophageal Cancer
Pleural Mesothelioma - Speciality:
-
Thoracic Surgery
- Gender:
-
Male
- Language:
-
English, Czech, Polish
Get to Know Dr. Boris Sepesi
Surgical oncologist Dr. Boris Sepesi utilizes endoscopic, minimally invasive and traditional surgical techniques to treat patients with complex thoracic malignancies such as mesothelioma at Cardiothoracic and Vascular Surgery Associates, part of HCA Healthcare’s HealthONE Physician Group in Aurora, Colorado.
Sepesi handles cases of pleural mesothelioma, lung cancer, esophageal cancer and chest wall tumors as part of a multidisciplinary, personalized approach to treatment.
He has many research interests, including chemotherapy, immunotherapy, and targeted therapy. A significant part of his work involves clinical trials of promising new therapies for his patients.
In his previous role, Sepesi co-authored a study that retrospectively compared and contrasted different and aggressive surgeries used for pleural mesothelioma cancer at MD Anderson over a 20-year span.
Specialties of Dr. Boris Sepesi
- Pleural mesothelioma
- Lung cancer
- Esophageal cancer
- Minimally invasive surgery
- Chest wall tumors
- Clinical trials
Dr. Boris Sepesi’s Experience and Education
- Cardiothoracic and Vascular Surgery Associates, HealthONE Physician Group, HCA Healthcare
- University of Texas MD Anderson Cancer Center
- University of Rochester Medical Center (Residency and fellowship)
- Jagiellonian University Medical College (M.D.)
Awards and Certifications
- American Board of Thoracic Surgery
- American Board of Surgery (Diplomat)
- Associate professor, University of Texas MD Anderson Cancer Center
- American College of Surgeons (Fellow)
- Ronald Belsey Esophageal Surgery Club
- Stuber scholarship, University of Rochester Medical Center
- Class president, Jagiellonian University Medical College
Mesothelioma Clinical Trials Under Dr. Boris Sepesi
- A phase I and II clinical trial to evaluate the safety and feasibility of using the neoadjuvant combination of nivolumab and ipilimumab for patients with resectable pleural mesothelioma.
Publications of Dr. Boris Sepesi
- Corsini, E.M. & Sepesi, B. (2020, March 1). Commentary: Salvage Resection For Stage IIIA Lung Cancer in the Era of Immunotherapy. Seminars In Thoracic And Cardiovascular Surgery.
- Shewale, J.B. et al. (2020, February 1). Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. The Annals of Thoracic Surgery.
- Mitchell, K.G. et al. (2020, January 1). Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer
- Nelson, D.B. et al. (2020, January). Persistent Opioid Use Among the Elderly After Lung Resection: A SEER-Medicare Study. Annals of Thoracic Surgery.